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Introduction
Urinary tract infections (UTI) are among most com-
mon bacterial diseases both in community and hospital 
settings. Due to their high rate of frequency, recurrence, 
complications as well as increasing antimicrobial resist-
ance, they pose a real challenge to medical professionals. 
Older people are more susceptible to UTI because 
their immune system is weaker, and comorbidities are 
often present (Aplay et al. 2018). Escherichia coli (E. coli)
remains the predominant isolated uropathogen in 
Poland accounting for 80% of all uncomplicated infec-
tions (Stefaniuk et al. 2016). However, in the presence 
of a urinary cathe ter, the spectrum of E. coli accounts 
for approximately 50% of total catheter-associated UTI 
(CAUTI), and other uropathogens become more preva-
lent (Flores-Mireles et al. 2015).
Of all hospital-associated UTI, 70–80% result from 
an indwelling urinary catheter, especially in older 
people, after surgical procedures and among patients 
staying in intensive care units (Temiz et al. 2012; 
Wójkowska-Mach et al. 2013; Piechota 2016). Catheter 
use is also associated with noninfectious outcomes, 
including mechanical trauma, mobility impairment as 
well as urethral strictures (Esposito et al. 2011; Hollings-
worth et al. 2013). Additionally, prolonged catheteriza-
tion increases the risk of biofilm formation in which 
uropathogens are difficult to treat with anti microbial 
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A b s t r a c t
A retrospective study was conducted among 498 patients with urinary tract infections (UTI) referred to our department from January 
2013 to December 2015. This study was performed to evaluate the etiology of UTI and the antibiotic susceptibility profile of Escherichia 
coli (E. coli) as the main etiological factor in different age groups. Urine samples were examined using standard microbiological methods. 
Three hundred sixty-three samples (72.9%) were identified as E. coli, of which 29 (8.0%) can produce extended-spectrum β-lactamases 
(ESBL). E. coli was highly sensitive to imipenem (100.0%), gentamicin (91.0%), nitrofurantoin (89.4%), amikacin (88.2%), piperacillin/
tazobactam (87.0%) and cephalosporins (79.7–89.5%). Low sensitivity was found in relation to fluoroquinolones (60.3–70.4%). E. coli was 
least sensitive to ampicillin (30.2%) and amoxicillin/clavulanic acid (49.9%). We observed a significant fall in susceptibility level to pipera-
cillin/tazobactam (68.4% vs. 88.8%; p = 0.017), amikacin (61.1% vs. 90.7%; p = 0.001), gentamicin (70.0% vs. 93.2%; p = 0.002), cefalexin 
(41.2% vs. 83.3%; p < 0.001), cefotaxime (63.6% vs. 89.4%; p = 0.002), ceftazidime (61.9% vs. 85.6%; p = 0.008), cefepime (73.7% vs. 91.1%; 
p = 0.025), ciprofloxacin (54.1% vs. 72.2%; p = 0.024) and norfloxacin (40.5% vs. 62.5%; p = 0.011) among patients with catheter-associated 
UTI (CAUTI) compared to those with non-CAUTI. A similar susceptibility profile was observed between different age groups. In the 
longevity, E. coli showed a higher sensitivity to cephalosporins than in the young-old group. E. coli susceptibility to fluoroquinolones was low, 
which excludes them as a first-line drug in our department. Nitrofurantoin may be used as an alternative drug to carbapenems. Monitoring 
of susceptibility pattern is of great importance.
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agents (Zalewska-Piatek et al. 2009). Therefore, before 
deciding to catheterize the bladder it is important to 
estimate indications individually.
An optimal empirical therapy for UTI requires 
under standing of local epidemiology and antimicrobial 
susceptibility profiles. Uropathogens have developed 
resistance mechanisms to commonly prescribed anti bio-
tics what limits treatment options of effective therapies. 
So, we conducted a study to describe clinical character-
istics of patients with UTI, including CAUTI, as well as 
to determine etiology and susceptibility profiles of most 
common urinary isolates in different age groups.
Experimental
Materials and Methods
A retrospective study was conducted on hospitalized 
adults from 1st January 2013 to 31st December 2015 in 
a  Department of Internal Medicine and Nephrology 
with Dialysis Centre of Regional Hospital in southern 
Poland. During this period 4512 patients (2452 women 
and 2060 men) were hospitalized in our department in 
whom we diagnosed 498 cases of UTI. Among these 
cases, a group with CAUTI was distinguished. In the 
study, we made a systematic analysis of medical records 
of patients with diagnosed UTI.
UTI was diagnosed based on a positive result of 
a  urine culture test with significant bacterial growth 
≥ 105 CFU/ml and a presence of at least one of the fol-
lowing symptoms: body temperature ≥ 37.5°C, dysuria, 
perineal pain, suprapubic pain or flank pain. Labora-
tory tests usually showed the elevated level of inflam-
matory markers and leucocyturia in urinalysis. Accord-
ing to the European Centre for Disease Prevention and 
Control (ECDC 2015), diagnostic criteria for CAUTI 
included the maintenance of a catheter in the bladder 
for at least 7 days. The patients were also categorized 
by age as follows: 19–74 years (young old), 75–85 years 
(old old) and > 85 years (longevity).
Urine for bacteriological examination was obtained 
from the middle stream but in catheterized patients 
after a catheter replacement with the hygiene and 
sterility principles preserved. All urine samples were 
inoculated in a Microbiology Department on Columbia 
agar with 5% sheep blood, Sabouarud agar and Chro-
mogenic media. Inoculated agar plates were incubated 
aerobically at 35–37°C for 18–24 hours. Colonies were 
counted on the inoculated medium and multiplied by 
the loop volume to determine bacterial count. Bacte-
rial identification was done by standard biochemical 
procedures, including Vitek 2 Compact system.
Antibiotic susceptibility testing (AST) as an in vitro 
assessment of activity of the antimicrobial drug was 
determined using the disc-diffusion and diffusion-gra-
dient (E-test) methods. Zone diameters for individual 
antimicrobial agents were translated into susceptible, 
intermediate and resistant categories. According to the 
European Committee on Antimicrobial Susceptibility 
Testing (EUCAST), intermediate sensitivity strains 
were classified as resistant. A susceptibility level was 
calculated by dividing the number of sensitive strains 
to the antimicrobial agent by the total number of strains 
in relation to which the sensitivity to a particular anti-
microbial agent was determined. Strains were tested 
against the following antibiotics: ampicillin, amoxicillin/ 
clavulanic acid, piperacillin/tazobactam, amikacin, gen-
tamicin, cefalexin, cefuroxime, cefotaxime, ceftazidime, 
cefepime, ciprofloxacin, norfloxacin, cotrimoxazole, 
imipenem and nitrofurantoin.
Because of E. coli predominance in the studied 
population, we analyzed susceptibility pattern only in 
reference to this uropathogen, including also division 
into age groups. The remaining microbes were not rep-
resentative enough to be analyzed in this issue.
We accepted p < 0.05 as the cut-off value for the 
level of statistical significance. The logistic regression 
test and chi-square test were used to compare indepen- 
dent variables. The calculations were carried out by the 
SPSS software (Statistical Package for the Social Scien-
ces, STATISTICS 20, Armonk, NY, USA).
Results
Among 4512 hospitalized patients, we recognized 
498 cases of UTI (11.0%), of which 60 were CAUTI 
(1.3%). The mean age was 74.8 ± 14.6  years (ranging 
from 19 to 101 years) without differences between 
CAUTI and non-CAUTI population (76.2 ± 10.4 vs. 
74.6 ± 15.0 years; p = 0.988). Hospitalization time was 
significantly longer in patients with CAUTI compared 
to those with non-CAUTI (13.63 ± 10.47 vs. 9.58 ± 6.66 
days; p = 0.002).
Table I presents the demographic and clinical char-
acteristics of the studied population. Females showed 
much higher prevalence of the total UTI as 319 (64.1%), 
and in the non-CAUTI group than in the CAUTI group 
(67.6% vs. 38.3%; p < 0.001). However, males were 
more common in the CAUTI group (61.7% vs. 32.4%; 
p < 0.001). Patients who developed catheter-associated 
infections had more frequently genitourinary tumors 
(15.0% vs. 7.3%; p = 0.047) and urine stasis in kidneys 
(8.3% vs. 4.1%; p = 0.001). In addition, 10 men were 
after prostatectomy. No significance was found for 
other diseases and risk factors.
E. coli was the predominant isolated uropathogen in 
the studied population (72.9%). However, its occurence 
in the CAUTI group was significantly smaller com-
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pared to non-CAUTI group (61.7% vs. 74.4%; p = 0.039) 
(Table  II). The occurrence of other microbes in the 
CAUTI and non-CAUTI groups were much lower: 
Proteus sp. (10.0% vs. 5.5%; p = 0.174), Staphylococcus 
sp. (8.3% vs. 1.6%; p = 0.004), Enterobacter sp. (6.7% vs. 
3.7%; p = 0.272), Klebsiella sp. (3.3% vs. 8.7%; p = 0.170) 
and Enterococcus sp. (3.3% vs. 2.0%; p = 0.532).
Production of extended-spectrum β-lactamases 
(ESBL) was found in 11.8% of total strains with the 
prevalence as follows: in the CAUTI (9/60; 15.0%) 
group and in the non-CAUTI (50/438; 11.4%) group. 
Enterobacter sp. were most frequently associated with 
ESBL production as 60.0% of all Enterobacter sp. iso-
lates was positive, followed by Klebsiella sp. (35.0%).
Table III presents susceptibility profile of E. coli in 
the studied population to various antimicrobial agents. 
E. coli showed the highest prevalence of susceptibility to 
imipenem (100.0%), followed by gentamicin (91.0%), 
nitrofurantoin (89.4%), amikacin (88.2%), piperacillin/
tazobactam (87.0%) and cephalosporins (79.7–89.5%). 
The prevalence of susceptibility was least to ampicillin 
(30.2%) and amoxicillin/clavulanic acid (49.9%). We 
Table II
Microbial uropathogens isolated from the urine samples.
n %
Pathogen
Total UTI CAUTI non-CAUTI
OR (95% CI) p-value
n %n %
E. coli  363 72.9% 37 61.7% 326 74.4% 0.55 (0.31–0.97) 0.039
Proteus sp.  30 6.0% 6 10.0% 24 5.5% 1.92 (0.75–4.90) 0.174
Staphylococcus sp. 12 2.4% 5 8.3% 7 1.6% 5.60 (1.72–18.24) 0.004
Enterobacter sp.  20 4.0% 4 6.7% 16 3.7% 1.88 (0.61–5.84) 0.272
Klebsiella sp. 40 8.0% 2 3.3% 38 8.7% 0.36 (0.09–1.54) 0.170
Enterococcus sp.  11 2.2% 2 3.3% 9 2.0% 1.64 (0.35–7.80) 0.532
Other 22 4.4% 4 6.7% 18 4.1% 1.67 (0.54–5.10) 0.371
Total 498 100.0% 60 100.0% 438 100.0% – –
Other pathogens:
Pseudonomas sp. (n = 6), Morganella morganii (n = 4), Acinetobacter baumanii (n = 3), Serratia sp. (n = 3), Citrobacter sp. (n = 2), 
Raoultella planticola (n = 1), Salmonella (n = 1), Stenotrophomonas maltophilia (n = 1), Streptococcus agalactiae (n = 1)
ESBL-producing pathogens responsible for CAUTI: E. coli (n = 6), Klebsiella sp. (n = 2), Enterobacter sp. (n = 1)
ESBL-producing pathogens responsible for non-CAUTI: E. coli (n = 23), Klebsiella sp. (n = 12), Enterobacter sp. (n = 11),
Proteus sp. (n = 4)
Table I
Characteristic of patients with UTI enrolled in the study.
Data are expressed as number and percentage.
One patient may have several co-existing diseases
n %
Characteristic
Total UTI
n = 498 (100%)
CAUTI
n = 60 (100%)
non-CAUTI
n = 438 (100%) OR (95% CI) p-value
Gender: Male 179 35.9% 37 61.7% 142 32.4% 3.35 (1.92–5.86) < 0.001
        Female 319 64.1% 23 38.3% 296 67.6% 0.30 (0.17–0.52) < 0.001
Hypertension  263 52.8% 37 61.7% 226 51.6% 1.51 (0.87–2.62) 0.145
Heart failure 174 34.9% 23 38.3% 141 32.2% 1.31 (0.75–2.29) 0.344
Diabetes mellitus 190 38.2% 18 30.0% 172 39.3% 0.72 (0.40–1.28) 0.258
Urolithiasis 22 4.4% 1 1.7% 21 4.8% 0.34 (0.04–2.55) 0.292
Bronchopneumonia 9 1.8% 1 1.7% 8 1.8% 0.91 (0.11–7.41) 0.931
Malignancy (total) 80 16.1% 11 18.3% 69 15.8% 1.34 (0.68–2.65) 0.405
Genitourinary malignancy 41 8.2% 9 15.0% 32 7.3% 2.24 (1.01–4.96) 0.047
Prostatic hyperplasia 57 11.4% 10 16.7% 47 10.7% 1.66 (0.79–3.50) 0.180
Urine stasis in kidneys 23 4.6% 5 8.3% 18 4.1% 4.34 (1.76–10.73) 0.001
Percutaneous nephrostomy 8 1.6% 1 1.7% 7 1.6 % 1.04 (0.13–8.63) 0.968
Hemodialysis 20 4.0% 2 3.3% 18 4.1% 0.80 (0.18–3.56) 0.774
Immunotherapy 26 5.2% 4 6.7% 22 5.0% 1.35 (0.45–4.06) 0.593
n %n %
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also observed a fall in sensitivity level of E. coli to antibi-
otics among CAUTI patients compared to non-CAUTI 
individuals, with the significant differences in relation 
to piperacillin/tazobactam (68.4% vs. 88.8%; p = 0.017), 
amikacin (61.1% vs. 90.7%; p = 0.001), gentamicin 
(70.0% vs. 93.2%; p = 0.002), cefalexin (41.2% vs. 83.3%; 
p < 0.001), cefotaxime (63.6% vs. 89.4%; p = 0.002), cef-
tazidime (61.9% vs. 85.6%; p = 0.008), cefepime (73.7% 
vs. 91.1%; p = 0.025), ciprofloxacin (54.1% vs. 72.2%; 
p = 0.024) and norfloxacin (40.5% vs. 62.5%; p = 0.011).
An antimicrobial susceptibility profile of E. coli 
depending on age groups was summarized in Table IV. 
The youngest group constituted the reference for other 
groups. E. coli showed a similar susceptibility level to 
most antimicrobial agents between different age groups. 
In the longevity, E. coli demonstrated higher sensitivity 
to cephalosporins than in the young-old group, with 
significant differences relating to cefalexin (93.9% 
vs. 74.3%; p = 0.011), cefotaxime (96.7% vs. 81.9%; 
p = 0.017) and cefepime (98.2% vs. 84.9%; p = 0.033).
Furthermore, we also carried out an analysis con-
cerning E. coli sensitivity to antimicrobial agents in 
patients with CAUTI and non-CAUTI, according to 
age groups. No significant variations in drug suscep-
tibility were noted among patients with catheter-asso-
ciated infections between age groups. The only excep-
tion concerned the longevity group with non-CAUTI, 
in whom E. coli showed significantly higher prevalence 
of susceptibility than in the young old group, relating to 
cefalexin (p = 0.019) and cefotaxime (p = 0.034).
Discussion
Urinary tract infection is emerging as an important 
community-acquired and nosocomial bacterial infec-
tion what was also confirmed by our 3-year analysis. It 
occurs on average in 1 per 10 of hospitalized patients 
and that was also presented in our previous study 
(Michno et al. 2016).
In our study, UTI mainly concerned older people 
who constituted the majority, as evidenced by average 
age of the studied population. The proportion of older 
people is rising constantly from 11% in 2012 and it is 
Beta-lactam antibacterials, penicylinns
Ampicillin 354 30.2% 36 19.4% 318 31.4% 0.53 (0.22–1.24) 0.143
AM/CL 361 49.9% 37 43.2% 324 50.6% 0.74 (0.37–1.48) 0.397
PIP/TZ  207 87.0% 19 68.4% 188 88.8% 0.27 (0.09–0.79) 0.017
Aminoglycosides
Amikacin 211 88.2% 18 61.1% 193 90.7% 0.16 (0.06–0.47) 0.001
Gentamicin 211 91.0% 20 70.0% 191 93.2% 0.17 (0.06–0.52) 0.002
Cephalosporins
Cefalexin 197 79.7% 17 41.2% 180 83.3% 0.14 (0.05–0.40) < 0.001
Cefuroxime 358 85.8% 36 75.0% 322 87.0% 0.45 (0.20–1.02) 0.057
Cefotaxime 238 87.0% 22 63.6% 216 89.4% 0.21 (0.08–0.55) 0.002
Ceftazidime 237 83.5% 21 61.9% 216 85.6% 0.27 (0.10–0.71) 0.008
Cefepime 210 89.5% 19 73.7% 191 91.1% 0.27 (0.09–0.85) 0.025
Antipseudomonal fluoroquinolones
Ciprofloxacin  361 70.4% 37 54.1% 324 72.2% 0.45 (0.23–0.90) 0.024
Norfloxacin 360 60.3% 37 40.5% 323 62.5% 0.41 (0.20–0.82) 0.011
Folate pathway inhibitors
Cotrimoxazole 358 72.3% 36 72.2% 322 72.4% 0.99 (0.46–2.14) 0.986
Antipseudomonal carbapenems
Imipenem 179 100.0% 18 100.0% 161 100.0% – –
Nitrofuran derivatives
Nitrofurantoin 357 89.4% 37 83.8% 320 90.0% 0.57 (0.22–1.48) 0.251
Table III
Susceptibility profile of E. coli isolates studied to various antimicrobial agents.
n’ % susc.
Antibiotics
Total UTI
(n = 363)
CAUTI
(n = 37)
non-CAUTI
(n = 326) OR (95% CI) p-value
n’ % susc.n’ % susc.
Abbrevations: Amoxicillin/clavulanic acid = AM/CL, Piperacillin/Tazobactam = PIP/TZ 
n’ – number of all determinations for a given antibiotic;  % susc. – % susceptibility
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supposed to reach 22% by 2050 (UN 2012). Thus, chal-
lenges associated with infections in older population 
require specific assessment.
Urinary tract catheterization is one of the most 
common reason of bacteriuria caused by tendency of 
bacteria to adhere to artificial materials. It is believed 
that CAUTI occurs at a rate of 3–7% per day of cathe-
terization and the incidences approach 100% within 
30 days (Lo et al. 2014). Among patients hospitalized in 
our department, CAUTI were diagnosed in 1.3% cases 
that was a slightly higher than in the study carried out 
in Australia – 0.9% (Gardner et al. 2014). In another 
study, CAUTI were reported in 2.2% of hospitalized 
patients of the urological and orthopedic department 
(Giles et al. 2015).
In the current study, CAUTI was significantly more 
frequent in men that was similar to the Korean report 
(Kim et al. 2017). The authors, like in our study, ana-
lyzed the characteristics of CAUTI and non-CAUTI 
patients. They observed that CAUTI occurred sig-
nificantly more often in patients with hypertension, 
those who used ventilators and after operations. In our 
analysis, CAUTI was more frequent in patients with 
genitourinary malignancy and urine stasis in kidneys. 
Patients with cancer have a greater tendency to acquire 
infections than general population due to cellular and 
humoral immune dysfunction, as well as complications 
of cancer therapy, including neutropenia or disruption 
of natural physical barriers (Thirumala et al. 2010). 
Urinary tract obstruction provides an opportunity for 
bacteria to adhere to urothelium and infect patients. 
In such case, effective antibiotic therapy as well as an 
appropriate urological intervention is necessary to pre-
vent recurrent UTI and septic complications.
The predominant uropathogen responsible for 
CAUTI in our study was E. coli, followed by Proteus 
sp. and Staphylococcus sp. In patients with non-CAUTI, 
apart from E. coli, we also frequently observed infec-
tions caused by Klebsiella sp. and Proteus sp. A lot of 
authors indicate a very similar bacterial flora (Krygiel 
et al. 2012; Kalal and Nagaraj 2016; Wang et al. 2016).
E. coli was the main etiological factor in both groups, 
however, its predominance was significantly smaller in 
catheter-associated infections. This is because CAUTI 
belong to complicated ones with higher rate of hospital-
acquired infections, in which prevalence of the E. coli 
is not as high as in uncomplicated UTI (Holecki et al. 
2015). In such a situation, other pathogens which are 
less commonly associated with UTI become more prev-
alent. Our study showed a significant increase of Staphy-
lococcus sp. isolates in patients with CAUTI (p = 0.004). 
Recent studies highlighted that Staphylococcus aureus 
is a common problem associated with urinary cathe-
terization, leading more often to bacteremia than other 
uropathogens (Muder et al. 2006; Baraboutis et al. 2010).
Proteus sp. were the second most prevalent cause 
of CAUTI and occurred almost twice more often than 
in the non-CAUTI in this study. According to some 
Ampicillin 132 31.1% 130 26.9% 92 33.7% 0.82 (0.48–1.40) 0.461 1.13 (0.64–1.99) 0.678
AM/CL 133 49.6% 133 51.1% 95 48.4% 1.06 (0.66–1.72) 0.806 0.95 (0.56–1.61) 0.858
PIP/TZ  73 86.3% 80 85.0% 54 90.7% 0.90 (0.36–2.23) 0.819 1.56 (0.50–4.85) 0.446
Amikacin 74 90.5% 83 81.9% 54 94.4% 0.47 (0.18–1.24) 0.127 1.78 (0.44–7.21) 0.422
Gentamicin 72 88.9% 85 89.4% 54 96.3% 1.06 (0.38–2.89) 0.916 3.25 (0.66–15.97) 0.147
Cefalexin 70 74.3% 78 75.6% 49 93.9% 1.07 (0.51–2.26) 0.849 5.31 (1.47–19.19) 0.011
Cefuroxime 132 85.6% 133 82.0% 93 91.4% 0.76 (0.40–1.47) 0.421 1.79 (0.75–4.28) 0.193
Cefotaxime 83 81.9% 95 85.3% 60 96.7% 1.28 (0.58–2.83) 0.548 6.40 (1.40–29.14) 0.017
Ceftazidime 83 80.7% 94 81.9% 60 90.0% 1.08 (0.51–2.31) 0.839 2.15 (0.79–5.87) 0.136
Cefepime 73 84.9% 82 87.8% 55 98.2% 1.28 (0.51–3.21) 0.602 9.58 (1.20–76.64) 0.033
Ciprofloxacin  132 72.0% 134 67.9% 95 71.6% 0.82 (0.49–1.39) 0.471 0.98 (0.55–1.76) 0.949
Norfloxacin 133 62.4% 132 59.1% 95 58.9% 0.87 (0.53–1.43) 0.581 0.86 (0.50–1.48) 0.598
Cotrimoxazole 130 74.6% 133 67.7% 95 75.8% 0.71 (0.42–1.22) 0.215 1.06 (0.58–1.97) 0.841
Imipenem 57 100.0% 74 100.0% 48 100.0% – – – –
Nitrofurantoin 132 91.7% 131 87.8% 94 88.3% 0.65 (0.29–1.47) 0.303 0.69 (0.28–1.66) 0.402
Table IV
Susceptibility profile of E. coli (n = 363) isolated from patients of different age groups.
Abbrevations: Amoxicillin/clavulanic acid = AM/CL, Piperacillin/Tazobactam = PIP/TZ
n’ – number of all determinations for a given antibiotic;  % susc. – % susceptibility
Antibiotics
19–74 years
(n = 133)
75–85 years
(n = 134)
> 85 years
(n = 96)
75–85 years
vs. 19–74 years
> 85 years vs.
19–74 years
n’ % susc. OR (95% CI) p-value OR (95% CI) p-valuen’ % susc.n’ % susc.
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reports, Proteus mirabilis is also supposed to be a fre-
quent reason of CAUTI, especially in males, with a ten-
dency to biofilm formation accounting for 17.9% of 
Enterobacteraceae family (Jacobsen et al. 2008; Moryl 
et al. 2013).
In the current study, Klebsiella sp. were the second 
common cause of non-CAUTI which is compatible 
with most publications (Farajnia et al. 2009; Abou-
Dobara et al. 2010). However, another study reported 
that Pseudomonas sp. were the second frequent iso-
lated microorganisms responsible for 8.7% of total UTI 
(Abejew et al. 2014).
Antimicrobial resistance is now accepted as a major 
problem in public health and patient care. It is mainly 
associated with an abuse of antimicrobial agents and 
makes it difficult to choose a proper empirical treat-
ment by medical practitioners, especially in cases 
of multidrug resistant strains (Pobiega et al. 2015). 
Uropathogens developed resistance mechanisms of 
which the most common is ESBL. Organisms produc-
ing ESBL are clinically relevant and remain an impor-
tant cause of failure of cephalosporins (Bradford 2001). 
In this study, Enterobacter sp. and Klebsiella sp. were the 
most frequently ones associated with ESBL production 
of all these species, followed by Proteus sp. and E. coli. 
Similar results were also reported by other authors from 
Poland (Sacha et al. 2007). E. coli as the predominant 
uropathogen was responsible for ESBL production in 
8.0% of total E. coli isolates being positive, similarly to 
the previous data from southern Poland (Pobiega et al. 
2013). For example, in France approximately 4.0% of 
E. coli isolates are ESBL producers, while in Mexico 
even 31.3% of E. coli isolates produce ESBL mechanism 
(Galindo-Méndez 2018; Zucconi et al. 2018).
Susceptibility of E. coli in the studied population was 
highest to imipenem and gentamicin (> 90.0%), and 
lowest to ampicillin as well as amoxicillin/clavulanic 
acid (< 50.0%). This is similar to the reports from other 
countries with the exception of gentamicin which was 
a less effective drug (Daoud et al. 2015; Li et al. 2017). 
It may be since in our country gentamicin is rarely used 
as the first empiric choice for UTI treatment. Although, 
imipenem was the most effective drug, it should not 
be administrated as an empirical drug unless infection 
is life threatening, as carbapenems are considered drugs 
of last resort.
It is important to point out that the minimum 
susceptibility rate to support empirical treatment of 
UTI is 80% of all the strains of a specific uropatho-
gen in a given region. According to these guidelines, 
the European Association of Urology (EAU) recom-
mend cotrimoxazole as a ﬁrst-line drug for empirical 
therapy in UTI (Grabe et al. 2009). In our study, 74.6% 
of E. coli isolates were susceptible to cotrimoxazole. 
Despite the fact that these values may vary among 
reports, the resistance rate of E. coli to cotrimoxazole 
in Europe tends to be above 20%, having also been 
reported higher than 30% (Guneysel et al. 2009; Schito 
et al. 2009). E. coli susceptibility to fluoroquinolones in 
the current study ranged from 60.3% (norfloxacin) to 
70.4% (ciprofloxacin) which was similar to the rates 
observed in Brazil and Korea (Reis et al. 2016; Park 
et al. 2017). Another study reported that E. coli was 
least sensitive to cephalosporins (7.0–34.0%) and fluo-
roquinolones (26.0–28.0%); however, a study was con-
ducted on a population from low socioeconomic strata 
(Kidwai et al. 2017). A good empirical choice seems 
to be nitrofurantoin but a study carried out in Poland 
showed a high proportion of resistance to nitrofuran-
toin among E. coli isolates (Stefaniuk et al. 2016). Ami-
kacin, as an infusion solution, may by administrated 
only in hospital settings. Cephalosporins also remain 
a good option for empirical treatment of UTI caused by 
E. coli because of relatively high sensitivity to this group 
of drugs and minor side effects. On the other hand, 
cephalosporins are commonly prescribed by medical 
professionals which causes a growing resistance to them 
among bacteria. Therefore, clinical practitioners as well 
as laboratory personnel should implement a program to 
detect and report resistant strains such as ESBL produc-
ing bacteria to control and limit the therapeutic failures.
Patients with CAUTI are a specific group in which 
treatment of the infection may by difficult due to 
a high resistance rate of uropathogens. In such a case, 
it is necessary to administer an adequate initial anti-
microbial therapy according to local antimicrobial 
susceptibility situation (Saurel et al. 2006). Inadequate 
empirical antimicrobial therapy extends treatment 
contributing to various complications and transfor-
mation into a chronic illness. Our analysis confirmed 
that E. coli isolates were significantly less sensitive 
to most antibiotics in the CAUTI group compared to 
non-CAUTI group. Nitrofurantoin (83.8%) besides 
imipenem (100.0%), seemed to be an optimal choice in 
cases of catheter-associated infections caused by E. coli, 
contrary to ampicillin (19.4%). This result is compat-
ible with another report (Albu et al. 2018). However, 
other authors found amikacin (100.0%) and cefepime 
(100.0%) to be superior to nitrofurantoin (92.8%) in 
susceptibility rate what is incompatible with our ana-
lysis (Piljic et al. 2013).
Regardless of the age groups among the popula-
tion analyzed in this study, E. coli showed sensitivity to 
most antibiotics, including: imipenem, nitrofurantoin, 
amikacin, gentamicin, piperacillin/tazobactam as well 
as cepha losporins. Moreover, in reference to our results, 
it may be helpful for medical practitioners to choose 
cefalexin, cefotaxime or cefepime in case of UTI caused 
by E. coli in the longevity group, because of their signifi-
cantly higher susceptibility rate compared to young-old 
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as well as old-old groups. Fluoroquinolones in our report 
turned out to have limited efficacy among patients with 
UTI, regardless of the age group. Thus, choosing them 
as first-line drugs in empiric therapy raises doubts and 
should be careful in admitted patients.
The results of this study can be used to construct 
a hospital formulary and internal procedure for anti-
biotics usage in case of UTI in a specific department. 
Our results can also be helpful for comparison between 
departments and hospitals interested in this issue.
There are some limitations to this study. First, we 
retrospectively collected data through electronic medi-
cal records. It was difficult to obtain all characteristics 
for analyzing risk factors such as previous antibiotics 
use and history of recurrent UTI due to unrecorded 
information. Second, this study was conducted only in 
a single center. Therefore, it is difficult to reflect the 
overall characteristics of our region. The current report 
suggests the need for further large-scale monitoring of 
epidemiology and susceptibility profiles of most com-
mon uropathogens causing UTI, including CAUTI, to 
improve the effectiveness of empirical treatment.
Conclusions
The presented study showed considerable bacterial 
resistance to common empirically used antibiotics in 
case of CAUTI. E. coli susceptibility to fluoroquinolo-
nes was relatively low, which indicates the necessity 
of exclusion this group of drugs as first-line for the 
empirical treatment of UTI in our department. Nitro-
furantoin as an alternative to carbapenems, can be used 
in empiric therapy of UTI, including CAUTI, regardless 
of the age group. Monitoring of susceptibility pattern is 
of great importance.
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